Sakara Signals | August 1, 2025

Curated insights at the intersection of pharma, AI, and digital transformation.

Top Signal

FDA Transparency Shift Gains Momentum

The FDA’s release of over 200 Complete Response Letters (CRLs) from 2020–2024 marks a pivotal move toward regulatory transparency. This unprecedented access is enabling pharma teams to analyze rejection trends, refine submission strategies, and build smarter regulatory workflows. AI tools are already being deployed to parse CRL language and predict approval outcomes, a signal that regulatory intelligence is entering a new era.

Read the full article on FDA.gov →

Trend Tracker

AI-Powered Pharma Operations Accelerate

Digital twins, predictive maintenance, and AI-driven quality systems are reshaping pharma operations. As workforce constraints and regulatory complexity grow, companies are prioritizing efficiency over expansion. The shift is driving investment in intelligent automation, with AI increasingly embedded in manufacturing, compliance, and supply chain optimization.

Explore the Forbes deep dive →

Market Moves

M&A Surge Reshapes Specialty Pharma

Johnson & Johnson’s $14.6B acquisition of Intra-Cellular Therapies and Sanofi’s $9.1B deal with Blueprint Medicines signal a new wave of consolidation. These strategic moves are prompting rapid digital integration across portfolios, with AI playing a key role in harmonizing data, streamlining R&D, and accelerating go-to-market timelines.

See the full analysis from DelMorgan & Co. →

Blind Spot

Digital Engagement Gaps in Pharma

A 2025 industry survey reveals that while 68% of pharma firms are investing in AI-powered insights, only 13% feel “very prepared” to deliver AI-driven customer experiences. Barriers include data privacy concerns, fragmented tech stacks, and high adoption costs. The gap between insight and execution is widening — and digital maturity is emerging as a key differentiator.

Read the Graphite Digital white paper →

This article was created in collaboration with GenAI and shaped by intentional human insight.

#FractionalConsulting #LifeSciences #DigitalTransformation #AI #Pharma

Amie Harpe Founder and Principal Consultant

Amie Harpe is a strategic consultant, IT leader, and founder of Sakara Digital, with 20+ years of experience delivering global quality, compliance, and digital transformation initiatives across pharma, biotech, medical device, and consumer health. She specializes in GxP compliance, AI governance and adoption, document management systems (including Veeva QMS), program management, and operational optimization — with a proven track record of leading complex, high-impact initiatives (often with budgets exceeding $40M) and managing cross-functional, multicultural teams. Through Sakara Digital, Amie helps organizations navigate digital transformation with clarity, flexibility, and purpose, delivering senior-level fractional consulting directly to clients and through strategic partnerships with consulting firms and software providers. She currently serves as Strategic Partner to IntuitionLabs on GxP compliance and AI-enabled transformation for pharmaceutical and life sciences clients. Amie is also the founder of Peacefully Proven (peacefullyproven.com), a wellness brand focused on intentional, peaceful living.

See Full Bio